| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/25/1997 | WO1997035007A1 Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use |
| 09/25/1997 | WO1997034929A1 Process for extraction of a growth factor complex |
| 09/25/1997 | WO1997034927A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/25/1997 | WO1997034924A1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/25/1997 | WO1997034921A1 Conjugated mucin peptide vaccines |
| 09/25/1997 | WO1997034897A1 Fused imidazole derivatives as multidrug resistance modulators |
| 09/25/1997 | WO1997034895A1 Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use |
| 09/25/1997 | WO1997034639A1 Animal model for transplantation |
| 09/25/1997 | WO1997034636A1 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| 09/25/1997 | WO1997034635A1 Anti-idiotypic antibody vaccines |
| 09/25/1997 | WO1997034632A1 Glycosylated humanized b-cell specific antibodies |
| 09/25/1997 | WO1997034621A1 Hla-a2.1 binding peptides and their uses |
| 09/25/1997 | WO1997034612A1 Bis-anthracyclines with high activity against doxorubicin resistant tumors |
| 09/25/1997 | WO1997034608A1 Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 09/25/1997 | WO1997034600A1 Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide |
| 09/25/1997 | WO1997034589A1 Triaryl methane compounds for sickle cell disease |
| 09/25/1997 | WO1997031116A3 Recombinant ribonuclease proteins |
| 09/25/1997 | WO1997026867A3 Solid instant-release forms of administration and process for producing the same |
| 09/25/1997 | WO1997019113A3 Monoclonal antiidiotypic antibodies (ab2) and uses thereof |
| 09/25/1997 | WO1997017446A3 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
| 09/25/1997 | DE19634159C1 Hybrid cells prepared by fusing malignant B cells with hybridoma that expresses antibodies |
| 09/25/1997 | DE19610955A1 Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid Combination preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl) - anilide and N- (4-trifluoromethylphenyl) -2-cyano-3- hydroxycrotonamide |
| 09/25/1997 | CA2250222A1 Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| 09/25/1997 | CA2249997A1 Chemokine alpha 2 |
| 09/25/1997 | CA2249739A1 Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use |
| 09/25/1997 | CA2249593A1 Bis-anthracyclines with high activity against doxorubicin resistant tumors |
| 09/25/1997 | CA2249585A1 Animal model for transplantation |
| 09/25/1997 | CA2249551A1 A kinase capable of site-specific phosphorylation of i.kappa.b.alpha. |
| 09/25/1997 | CA2249395A1 Conjugated mucin peptide vaccines |
| 09/25/1997 | CA2249179A1 Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use |
| 09/25/1997 | CA2248843A1 Process for extraction of a growth factor complex |
| 09/25/1997 | CA2248629A1 Enzymes combinations for destroying proliferative cells |
| 09/25/1997 | CA2243509A1 Anti-idiotypic antibody vaccines |
| 09/25/1997 | CA2242342A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/24/1997 | EP0796855A1 Inhibitors of bone resorption and vitronectin receptor antagonists |
| 09/24/1997 | EP0796843A2 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives |
| 09/24/1997 | EP0796620A1 An anti-viral and anti-cancer agent from "Aspalathus Linearis" |
| 09/24/1997 | EP0796325A1 Human vascular ibp-like growth factor |
| 09/24/1997 | EP0796280A2 Murine monoclonal anti-idiotype antibody 3h1 |
| 09/24/1997 | EP0796277A1 Reagents and processes for targeting mutant epidermal growth factor receptors |
| 09/24/1997 | EP0796272A1 Antitumor agents isolated from intestinal mucosa, a method for their isolation and their application |
| 09/24/1997 | EP0796266A1 Anti-tumour agents |
| 09/24/1997 | EP0796260A1 Rapamycin 42-oximes and hydroxylamines |
| 09/24/1997 | EP0796113A2 Stable n-terminally linked dtpa:protein compositions and methods |
| 09/24/1997 | EP0796103A1 Use of incense in the treatment of alzheimer's disease |
| 09/24/1997 | EP0750609A4 Isoprenyl transferase inhibitors |
| 09/24/1997 | EP0667864B1 Tricyclic compounds with pharmaceutical activity |
| 09/24/1997 | EP0617705B1 Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them |
| 09/24/1997 | EP0521985B1 Chimeric antibodies with receptor binding ligands in place of their constant region |
| 09/24/1997 | CN1160404A Pharmaceutical compositions contg. estra-1,3,5C10-triene derivs. |
| 09/24/1997 | CN1160402A Purine and guanine compounds as inhibitors of PNP |
| 09/24/1997 | CN1160351A Compounds and methods for treatment of cancer |
| 09/24/1997 | CN1160045A Matrix metalloprotease inhibitors |
| 09/24/1997 | CN1160042A Ortho-substd. benzoyl guanidines, their preparing process and use as medicine and diagnostic reagent, and medicine contg. same |
| 09/24/1997 | CN1160041A Ortho-substd. benzoyl guanidines, their preparing process and use as medicine and diagnostic reagent, and medicine contg. same |
| 09/24/1997 | CN1159950A Bioadhesive pharmaceutical composition for controlled release of active principles |
| 09/24/1997 | CN1035925C Method for preparation of cytotropic non-homogeneous molecular lipid |
| 09/23/1997 | US5670638 2-bromo- and 2-nitroxy derivatives of 3-bromo- and 3,3-dibromo-4-oxo-azetidines, and preparation |
| 09/23/1997 | US5670537 Method for effecting tumor regression with a low dose, short infusion taxol regimen |
| 09/23/1997 | US5670536 Pharmaceutical composition based on taxoids |
| 09/23/1997 | US5670530 Anti-cancer composition comprising rhodacyanine compound and cyclodextrin |
| 09/23/1997 | US5670518 Antitumor agents; viricides |
| 09/23/1997 | US5670512 Skin disorders; reductase inhibitors |
| 09/23/1997 | US5670503 Prophylactic and therapeutic treatment of interleukin-1 and tumor necrosis factor mediated diseases such as inflammatory diseases, autoimmune diseases |
| 09/23/1997 | US5670502 Method of tumor treatment |
| 09/23/1997 | US5670500 Water soluble camptothecin analogs |
| 09/23/1997 | US5670493 Angiogenesis inhibitors |
| 09/23/1997 | US5670491 Photodynamic chemotherapy of tumors |
| 09/20/1997 | CA2199923A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors |
| 09/18/1997 | WO1997034146A1 Inhibiting protein interactions |
| 09/18/1997 | WO1997034011A1 Producer of an anti-tumour melanin-containing preparation 'astromelanin' |
| 09/18/1997 | WO1997034010A1 Producer of an anti-tumour melanin-containing preparation 'astromelanin' |
| 09/18/1997 | WO1997034009A1 Recombinant adenoviral vectors for human tumour gene therapy |
| 09/18/1997 | WO1997033996A2 Human bikunin |
| 09/18/1997 | WO1997033995A2 Extracellular matrix signalling molecules |
| 09/18/1997 | WO1997033993A1 Human membrane antigen tm4 superfamily protein and dna encoding this protein |
| 09/18/1997 | WO1997033919A1 Thioureido-cyclodextrins particularly useful for solubilising antitumoral and antiparasitic agents, and methods for preparing same |
| 09/18/1997 | WO1997033911A1 Persephin and related growth factors |
| 09/18/1997 | WO1997033904A1 Death domain containing receptors |
| 09/18/1997 | WO1997033894A1 Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes |
| 09/18/1997 | WO1997033887A1 Spirocycle integrin inhibitors |
| 09/18/1997 | WO1997033881A1 Bicyclic-aromatic compounds |
| 09/18/1997 | WO1997033856A1 Diaromatic propynyl or dienyl compounds |
| 09/18/1997 | WO1997033628A1 Polymeric delivery of radionuclides and radiopharmaceuticals |
| 09/18/1997 | WO1997033611A1 Method of killing target cells in harvested cell populations with one or more immunotoxins |
| 09/18/1997 | WO1997033602A1 Peptides with increased binding affinity for hla molecules |
| 09/18/1997 | WO1997033593A1 A product of heat treatment of uronic acid, food, drink or drug including the product |
| 09/18/1997 | WO1997033578A1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment |
| 09/18/1997 | WO1997033572A1 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 09/18/1997 | WO1997033552A1 Water soluble paclitaxel prodrugs |
| 09/18/1997 | WO1997022695A3 Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer |
| 09/18/1997 | CA2249733A1 Spirocycle integrin inhibitors |
| 09/18/1997 | CA2248998A1 Inhibiting protein interactions |
| 09/18/1997 | CA2248765A1 Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment |
| 09/18/1997 | CA2248657A1 Peptides with increased binding affinity for hla molecules |
| 09/18/1997 | CA2248648A1 A product of heat treatment of uronic acid, food, drink or drug including the product |
| 09/18/1997 | CA2248620A1 Method of killing target cells in harvested cell populations with one or more immunotoxins |
| 09/18/1997 | CA2248612A1 Recombinant adenoviral vectors for human tumour gene therapy |
| 09/18/1997 | CA2248549A1 Extracellular matrix signalling molecules |
| 09/18/1997 | CA2248355A1 Human membrane antigen tm4 superfamily protein and dna encoding this protein |